CA2249607A1 - Inhibiteurs de transferase de farnesyl-proteine - Google Patents
Inhibiteurs de transferase de farnesyl-proteine Download PDFInfo
- Publication number
- CA2249607A1 CA2249607A1 CA002249607A CA2249607A CA2249607A1 CA 2249607 A1 CA2249607 A1 CA 2249607A1 CA 002249607 A CA002249607 A CA 002249607A CA 2249607 A CA2249607 A CA 2249607A CA 2249607 A1 CA2249607 A1 CA 2249607A1
- Authority
- CA
- Canada
- Prior art keywords
- substituted
- alkyl
- unsubstituted
- aryl
- hydrogen
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/64—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms, e.g. histidine
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D233/70—One oxygen atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
Landscapes
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Urology & Nephrology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Ophthalmology & Optometry (AREA)
- Virology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
Cette invention concerne des composés permettant d'inhiber la transférase de farnésyl-protéine (FTase), ainsi que la farnésylation de la protéine oncogène Ras. Cette invention concerne également des compositions chimiothérapeutiques contenant les composés susmentionnés, ainsi que des procédés permettant d'inhiber la transférase de farnésyl-protéine et la farnésylation de la protéine oncogène Ras.
Applications Claiming Priority (8)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US1459296P | 1996-04-03 | 1996-04-03 | |
US60/014,592 | 1996-04-03 | ||
GBGB9613462.2A GB9613462D0 (en) | 1996-06-27 | 1996-06-27 | Inhibitors of farnesyl-protein transferase |
GB9613462.2 | 1996-06-27 | ||
US2264796P | 1996-07-24 | 1996-07-24 | |
US60/022,647 | 1996-07-24 | ||
GB9617277.0 | 1996-08-16 | ||
GBGB9617277.0A GB9617277D0 (en) | 1996-08-16 | 1996-08-16 | Inhibitors of farnesyl-protein transferase |
Publications (1)
Publication Number | Publication Date |
---|---|
CA2249607A1 true CA2249607A1 (fr) | 1997-10-09 |
Family
ID=27451473
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA002249607A Abandoned CA2249607A1 (fr) | 1996-04-03 | 1997-04-01 | Inhibiteurs de transferase de farnesyl-proteine |
Country Status (5)
Country | Link |
---|---|
EP (1) | EP0891361A1 (fr) |
JP (1) | JP2000507590A (fr) |
AU (1) | AU706150B2 (fr) |
CA (1) | CA2249607A1 (fr) |
WO (1) | WO1997036901A1 (fr) |
Families Citing this family (37)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6015817A (en) * | 1996-12-05 | 2000-01-18 | Merck & Co., Inc. | Inhibitors of farnesyl-protein transferase |
US5939439A (en) * | 1996-12-30 | 1999-08-17 | Merck & Co., Inc. | Inhibitors of farnesyl-protein transferase |
US6093737A (en) * | 1996-12-30 | 2000-07-25 | Merck & Co., Inc. | Inhibitors of farnesyl-protein transferase |
US6127390A (en) * | 1997-10-02 | 2000-10-03 | Merck & Co., Inc. | Inhibitors of prenyl-protein transferase |
PL340729A1 (en) | 1997-11-28 | 2001-02-26 | Lg Chemical Ltd | Imidazolic derivatives exhibiting inhibitive activity in respect to pharnesil transferase and method of obtaining them |
EP1045843A4 (fr) * | 1997-12-04 | 2001-10-24 | Merck & Co Inc | Inhibiteurs de la farnesyl-proteine transferase |
US6420555B1 (en) | 1998-06-16 | 2002-07-16 | Societe De Conseils De Recherches Et D'applications Scientifiques, S.A.S. | Imidazolyl derivatives |
ES2216535T3 (es) * | 1998-06-16 | 2004-10-16 | Societe De Conseils De Recherches Et D'applications Scientifiques S.A.S. | Derivados de imidazolilo. |
US6511978B1 (en) * | 1999-04-13 | 2003-01-28 | Lg Life Sciences, Ltd. | Pyrrole derivatives useful for farnesyl transferase inhibitors and their preparations |
EP1420015A1 (fr) * | 1999-06-11 | 2004-05-19 | Societe De Conseils De Recherches Et D'applications Scientifiques S.A.S. | Dérivés de l'imidazole |
CA2413245A1 (fr) | 2000-06-30 | 2002-01-10 | Bristol-Myers Squibb Pharma Company | N-ureidoheterocycloaklyl-piperidines utilises comme modulateurs de l'activite du recepteur de la chimiokine |
US7211595B2 (en) | 2000-11-30 | 2007-05-01 | Abbott Laboratories | Farnesyltransferase inhibitors |
US20020115640A1 (en) * | 2000-11-30 | 2002-08-22 | Claiborne Akiyo K. | Farnesyltransferase inhibitors |
JP2006502107A (ja) | 2002-07-02 | 2006-01-19 | エフ.ホフマン−ラ ロシュ アーゲー | Ccr−3レセプターアンタゴニストixとしての2,5−置換ピリミジン誘導体 |
MX2007000885A (es) | 2004-07-23 | 2007-03-12 | Pfizer | Derivados de piridina. |
EP2129660A2 (fr) | 2006-12-19 | 2009-12-09 | Pfizer Products Inc. | Dérivés de nicotinamide en tant qu'inhibiteurs de h-pgds et leur utilisation pour le traitement de maladies liées aux prostaglandines d2 |
UY30892A1 (es) | 2007-02-07 | 2008-09-02 | Smithkline Beckman Corp | Inhibidores de la actividad akt |
JP2010519328A (ja) | 2007-02-26 | 2010-06-03 | ファイザー・プロダクツ・インク | H−pgdsの阻害剤としてのニコチンアミド誘導体およびプロスタグランジンd2が媒介する疾患の治療のためのそれらの使用 |
JP2010532381A (ja) | 2007-06-29 | 2010-10-07 | サネシス ファーマシューティカルズ, インコーポレイテッド | Rafキナーゼ阻害剤として有用な複素環式化合物 |
CL2008001933A1 (es) | 2007-06-29 | 2009-09-25 | Millennium Pharm Inc | Compuestos derivados de pirimidina, inhibidores de la raf quinasa; compuestos intermediarios; procedimiento de preparacion; composicion farmaceutica; y su uso para tratar trastornos proliferativos, cardiacos, neurodegenerativos, inflamatorios, oseos, inmunologicos enfermedad viral, entre otros. |
PE20110843A1 (es) | 2008-09-22 | 2011-12-08 | Cayman Chem Co | Derivados de 5-(1h-imidazol-5-il)-2-fenilpirimidina, como inhibidores de prostaglandina d sintasa hematopoyetica |
EP2414344A1 (fr) | 2009-03-31 | 2012-02-08 | ArQule, Inc. | Composés indolo-pyridinone substitués |
EP2730561B1 (fr) * | 2010-04-06 | 2015-10-14 | Nippon Soda Co., Ltd. | Méthodes de préparation de composés hétérocycliques haloalkylés contenant de l'azote |
AU2014201038B2 (en) * | 2010-04-06 | 2015-08-06 | Nippon Soda Co., Ltd. | Nitrogen-containing heterocyclic compound and method for producing same |
US8940742B2 (en) | 2012-04-10 | 2015-01-27 | Infinity Pharmaceuticals, Inc. | Heterocyclic compounds and uses thereof |
BR112016007467B1 (pt) | 2013-10-04 | 2022-09-20 | Infinity Pharmaceuticals, Inc | Compostos heterocíclicos e usos dos mesmos |
WO2015051241A1 (fr) | 2013-10-04 | 2015-04-09 | Infinity Pharmaceuticals, Inc. | Composés hétérocycliques et leurs utilisations |
JP6701088B2 (ja) | 2014-03-19 | 2020-05-27 | インフィニティー ファーマシューティカルズ, インコーポレイテッド | Pi3k−ガンマ媒介障害の治療で使用するための複素環式化合物 |
US9975874B2 (en) | 2014-07-28 | 2018-05-22 | Merck Sharp & Dohme Corp. | Factor XIa inhibitors |
WO2016054491A1 (fr) | 2014-10-03 | 2016-04-07 | Infinity Pharmaceuticals, Inc. | Composés hétérocycliques et leurs utilisations |
EP3319968A1 (fr) | 2015-07-06 | 2018-05-16 | Rodin Therapeutics, Inc. | N-aminophényl-amides hétérocycliques en tant qu'inhibiteurs de l'histone désacétylase |
RS62639B1 (sr) | 2015-07-06 | 2021-12-31 | Alkermes Inc | Hetero-halo inhibitori histonskih deacetilaza |
EP3350183A1 (fr) | 2015-09-14 | 2018-07-25 | Infinity Pharmaceuticals, Inc. | Formes solides de dérivés d'isoquinolinone, leur procédé de fabrication, compositions les comprenant et méthodes d'utilisation de celles-ci |
WO2017161116A1 (fr) | 2016-03-17 | 2017-09-21 | Infinity Pharmaceuticals, Inc. | Isotopologues de composés isoquinolinone et quinazolinone et leurs utilisations comme inhibiteurs de la kinase pi3k |
US10919914B2 (en) | 2016-06-08 | 2021-02-16 | Infinity Pharmaceuticals, Inc. | Heterocyclic compounds and uses thereof |
MA47305A (fr) | 2017-01-11 | 2019-11-27 | Rodin Therapeutics Inc | Inhibiteurs bicycliques d'histone désacétylase |
EP3664802B1 (fr) | 2017-08-07 | 2022-02-23 | Alkermes, Inc. | Inhibiteurs bicycliques de la histone déacétylase |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB2162513B (en) * | 1984-06-25 | 1988-01-20 | Toyama Chemical Co Ltd | Dihydropyridine derivatives |
US5633376A (en) * | 1990-12-28 | 1997-05-27 | Neurogen Corporation | Certain aminomethyl phenylimidazole derivatives; and 4-aryl substituted piperazinyl and piperidinylmethyl phenylimidazole derivatives; a new class of dopamine receptor subtype ligands |
US5159083A (en) * | 1990-12-28 | 1992-10-27 | Neurogen Corporation | Certain aminomethyl phenylimidazole derivatives; a class of dopamine receptor subtype specific ligands |
IT1255802B (it) * | 1992-08-07 | 1995-11-16 | Luso Farmaco Inst | Derivati imidazolici ad attivita' a ii antagonista |
-
1997
- 1997-04-01 CA CA002249607A patent/CA2249607A1/fr not_active Abandoned
- 1997-04-01 EP EP97920000A patent/EP0891361A1/fr not_active Withdrawn
- 1997-04-01 WO PCT/US1997/005304 patent/WO1997036901A1/fr not_active Application Discontinuation
- 1997-04-01 JP JP9535534A patent/JP2000507590A/ja active Pending
- 1997-04-01 AU AU24301/97A patent/AU706150B2/en not_active Ceased
Also Published As
Publication number | Publication date |
---|---|
EP0891361A1 (fr) | 1999-01-20 |
JP2000507590A (ja) | 2000-06-20 |
AU706150B2 (en) | 1999-06-10 |
AU2430197A (en) | 1997-10-22 |
WO1997036901A1 (fr) | 1997-10-09 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CA2249607A1 (fr) | Inhibiteurs de transferase de farnesyl-proteine | |
US5872136A (en) | Arylheteroaryl inhibitors of farnesyl-protein transferase | |
US5854264A (en) | Inhibitors of farnesyl-protein transferase | |
AU714851B2 (en) | Inhibitors of farnesyl-protein transferase | |
US5854265A (en) | Biheteroaryl inhibitors of farnesyl-protein transferase | |
US5883105A (en) | Inhibitors of farnesyl-protein transferase | |
US5939557A (en) | Inhibitors of farnesyl-protein transferase | |
US5859035A (en) | Arylheteroaryl inhibitors of farnesyl-protein transferase | |
US5874452A (en) | Biheteroaryl inhibitors of farnesyl-protein transferase | |
AU716381B2 (en) | Inhibitors of farnesyl-protein transferase | |
CA2276081A1 (fr) | Inhibiteurs de farnesyl-proteine transferase | |
AU715606B2 (en) | Inhibitors of farnesyl-protein transferase | |
CA2249641A1 (fr) | Inhibiteurs de farnesyl-proteine transferase | |
CA2250353A1 (fr) | Inhibiteurs de la farnesyl-proteine transferase | |
CA2250204A1 (fr) | Inhibiteurs de la farnesyl-proteine transferase | |
CA2249645A1 (fr) | Inhibiteurs de la farnesyl-proteine transferase | |
CA2249604A1 (fr) | Inhibiteurs de farnesyl-proteine transferase | |
AU704792B2 (en) | Inhibitors of farnesyl-protein transferase | |
CA2250231A1 (fr) | Inhibiteurs de la farnesyl-proteine transferase | |
AU706314B2 (en) | Inhibitors of farnesyl-protein transferase | |
CA2250460A1 (fr) | Inhibiteurs de transferase de farnesyl-proteine |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FZDE | Dead |